NetraMark Holdings debuts on TSX with AI tech to improve clinical trials in pharma.

NetraMark Holdings Inc., a Toronto-based company specializing in AI technology for the pharmaceutical industry, celebrated its new listing on the Toronto Stock Exchange (TSX). Their flagship AI product, NetraAI, analyzes complex clinical trial data to identify patient subgroups and treatment signals that traditional methods miss, helping to optimize trial design and decision-making. This listing marks a significant step for NetraMark as it aims to support better clinical development and precision medicine. The company’s leadership, alongside TSX officials, officially opened the market to mark the occasion.